Vaccinated adults had a 74 percent lower risk of dying from COVID-19—and a 25 percent lower risk of dying, period.
Cedars-Sinai scientists have created a new experimental drug called TY1 that helps the body repair damaged DNA and restore ...
KAIST researchers have developed a method that attaches DNA fragments to mRNA to slow the onset of protein production, ...
Spatial RNA medicine combines transcriptomics and RNA therapeutics, mapping gene expression in tissues to enhance precision ...
From enzymes and lipid nanoparticles to large-scale process design, four global innovators redefine RNA-based medicine development and delivery.
Competitive Landscape, Recent Expansions, Partnerships and Collaborations, Big Pharma Initiatives and Cost Price Analysis" report has been added to ResearchAndMarkets.com's offering. The ...
The Wistar Institute, an international biomedical research leader in cancer, immunology, and infectious disease, is pleased ...
RNA, widely known from the COVID-19 vaccine, is not actually a "therapeutic agent," but a technology that delivers the ...
The vaccine developers market shows significant opportunities through increased demand, collaborative partnerships, and ...
RNA, widely known from the COVID-19 vaccine, is not actually a "therapeutic agent," but a technology that delivers the blueprint for functional ...
RNA, widely known from the COVID-19 vaccine, is not actually a “therapeutic agent,” but a technology that delivers the ...
Fluorogenic DNA aptamers produce light only in the correct structural state, enabling programmable molecular logic, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback